The House voted on Thursday on a bill to cap insulin prices at just $35 a month, easing the burden for millions of Americans that spend thousands of dollars a year on the life-saving drug. The legislation, which passed 232-193 Thursday, would over relief to privately insured patients with slimmer plans and those who are enrolled in Medicare. It would not help the uninsured. The plan would not take effect until 2023, and still needs to make it through the Senate. The bill caps the cost-sharing for a monthly insulin supply at $35 or 25 percent of a plan's negotiated price, whichever is lower. It does not, however, target the pharmaceutical companies that have hiked the price of the drug, instead targeting a person's insurers and employers to offer lower prices.
Load More
Load More